Okay, so reading that paper more closely it appears that many of the cohort were from pre DAA treatments.

Here is a more recent one looking only at DAAs.

“Conclusion. Treatment of chronic HCV with DAAs leads to clinically relevant reduction in liver fibrosis over the first year post-treatment, measured by Fibroscan, even after controlling for elevated ALT”

https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofw172.310/2636806/Direct-Acting-Antiviral-DAA-Therapy-for-Chronic

The summary is that 51.1% had improved so far but that consisted of just those who improved by greater that 30% within the first 12 months of treatment and 57% of the cohort had “significant fibrosis” to begin with.

It is still early days for DAA treatments to be followed up long term and over time I would expect larger cohort studies and better long term results. If you google something like “fibrosis regression after DAA treatment” there are other recent trials that reach similar conclusions and I didn’t see anyone attempting to claim what you have been told.